Elexacaftor, tezacaftor, and ivacaftor (ETI) triple combination therapy, first licensed in the United States (US) in 2019, has rapidly become standard of care in most high-income countries (HIC) for people with CF (pwCF) aged 6 years and older with CFTR variants responsive to ETI, the commonest being F508del. This evidence concerns the gene CFTR and cystic fibrosis.